 |
Scil Proteins builds its commercialization strategy on the following business model: - Develop and partner Affilin® technology and therapeutics for indications where conventional approaches remain ineffective, with high unmet medical need, straight forward clinical development conceptions, clear reimbursement options for payers and lucrative markets. Two proprietary Affilin® compounds will be pursued into the clinical Phase I, for further development Scil is looking for partners with clinical development and marketing expertise for out-licensing.
- The Affilin® platform is offered to biotechnology and pharmaceutical companies looking for powerful drug discovery platform delivering effective, drugable and manufacturable new biological entities for out-licensing.
|
|
|
|
